董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Gerard Michel | 男 | CEO and Director | 59 | 147.21万美元 | 未持股 | 2023-05-01 |
| John Sylvester | 男 | Non-Executive Chairman | 59 | 10.11万美元 | 未持股 | 2023-05-01 |
| Gilad Aharon | -- | Director | 49 | 10.21万美元 | 未持股 | 2023-05-01 |
| Steven Salamon | 男 | Director | 57 | 11.31万美元 | 未持股 | 2023-05-01 |
| Roger G. Stoll | 男 | Director | 80 | 14.61万美元 | 未持股 | 2023-05-01 |
| Elizabeth Czerepak | 女 | Director | 67 | 12.21万美元 | 未持股 | 2023-05-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Gerard Michel | 男 | CEO and Director | 59 | 147.21万美元 | 未持股 | 2023-05-01 |
| Johnny John | 男 | Senior Vice President Clinical Development and Medical Affairs | 59 | 73.75万美元 | 未持股 | 2023-05-01 |
| John Purpura | 男 | Chief Operating Officer | 61 | 80.43万美元 | 未持股 | 2023-05-01 |
董事简历
中英对照 | 中文 | 英文- Gerard Michel
-
Gerard Michel，他于2014年6月加入Vericel公司，拥有制药行业跨多个功能领域的25年以上的经验。他拥有业务开发、筹集资金和执行成功的金融交易的丰富经验。他此前曾担任Biodel公司的首席财务官兼公司开发副总裁（从2007年11月到2014年5月），在那里他曾监管战略开发、融资和资本结构管理、营销努力、投资者关系，以及财务报告和内部控制。任职Biodel公司之前（从2002年8月到2007年11月），他曾担任NPS Pharmaceuticals公司的首席财务官兼公司开发副总裁，在那里他曾领导第一个银团皇室货币化。此前，他曾担任Booz Allen Hamilton公司的负责人，也曾担任Lederle Labs和Wyeth Labs的多种商业职务。他持有the University of Rochester School of Medicine的微生物学硕士学位、the Simon School of Business的工商管理硕士学位，以及the University of Rochester的生物学与地质学学士学位。
Gerard Michel was appointed to Delcath Systems, Inc. Board in October 2020. Mr. Michel has over 30 years of experience in the pharmaceutical and medical technology industries across multiple functional areas. Prior to joining the Company as its Chief Executive Officer on October 1 2020 he was Chief Financial Officer of Vericel Corp., a biopharmaceutical company, since June 2014 where he was a key member of the management team which integrated a transformative acquisition and revised the company's business model from a research focused company to a fully integrated, profitable commercial business. Mr. Michel also served as Chief Financial Officer and Vice President, Corporate Development of Biodel, Inc. from November 2007 to May 2014 and Chief Financial Officer and Vice President of Corporate Development of NPS Pharmaceuticals Inc. from August 2002 to November 2007. Prior to that, Mr. Michel was a Principal at Booz Allen and held a variety of commercial roles at both Lederle Labs and Wyeth Labs. Mr. Michel holds a M.S in Microbiology from the University of Rochester School of Medicine, an M.B.A. from the Simon School of Business, and a B.S. in both Biology and Geology from the University of Rochester. - Gerard Michel，他于2014年6月加入Vericel公司，拥有制药行业跨多个功能领域的25年以上的经验。他拥有业务开发、筹集资金和执行成功的金融交易的丰富经验。他此前曾担任Biodel公司的首席财务官兼公司开发副总裁（从2007年11月到2014年5月），在那里他曾监管战略开发、融资和资本结构管理、营销努力、投资者关系，以及财务报告和内部控制。任职Biodel公司之前（从2002年8月到2007年11月），他曾担任NPS Pharmaceuticals公司的首席财务官兼公司开发副总裁，在那里他曾领导第一个银团皇室货币化。此前，他曾担任Booz Allen Hamilton公司的负责人，也曾担任Lederle Labs和Wyeth Labs的多种商业职务。他持有the University of Rochester School of Medicine的微生物学硕士学位、the Simon School of Business的工商管理硕士学位，以及the University of Rochester的生物学与地质学学士学位。
- Gerard Michel was appointed to Delcath Systems, Inc. Board in October 2020. Mr. Michel has over 30 years of experience in the pharmaceutical and medical technology industries across multiple functional areas. Prior to joining the Company as its Chief Executive Officer on October 1 2020 he was Chief Financial Officer of Vericel Corp., a biopharmaceutical company, since June 2014 where he was a key member of the management team which integrated a transformative acquisition and revised the company's business model from a research focused company to a fully integrated, profitable commercial business. Mr. Michel also served as Chief Financial Officer and Vice President, Corporate Development of Biodel, Inc. from November 2007 to May 2014 and Chief Financial Officer and Vice President of Corporate Development of NPS Pharmaceuticals Inc. from August 2002 to November 2007. Prior to that, Mr. Michel was a Principal at Booz Allen and held a variety of commercial roles at both Lederle Labs and Wyeth Labs. Mr. Michel holds a M.S in Microbiology from the University of Rochester School of Medicine, an M.B.A. from the Simon School of Business, and a B.S. in both Biology and Geology from the University of Rochester.
- John Sylvester
-
John Sylvester于2019年7月被任命为公司董事。他目前担任Curium Pharma&8217；s SPECT和国际业务的首席执行官。此前，他曾担任BTG plc（他于2011年加入该公司）的首席商务官，并领导其介入肿瘤和介入血管业务，也曾担任首席开发官，负责战略、并购和市场准入。最终以42亿美元的价格退出波士顿科学公司。任职BTG公司之前，John曾担任BioComplobles plc的董事总经理，负责建立他们的介入肿瘤业务，从而以1.66亿英镑成功退出BTG公司。John加入BioConfectables公司之前，他曾担任Baxter梦百合公司的营销Vice President，负责位于布鲁塞尔的价值7.5亿新元的欧洲药物输送业务，随后加入苏黎世公司，负责六个战略业务部门，包括药物、设备和药物设备组合。在此之前，John在工业部门担任多个高级商业角色。在巴克斯特·梦百合之前，约翰是一家矿产公司的总经理，该公司在三大洲拥有40亿美元的资产，5亿美元的销售额和1500名员工。John以生物化学和应用分子生物学联合荣誉毕业于University of Manchester Institute of Science and Technology U.M.I.S.T.。
John Sylvester was appointed as a director of the Company in July 2019. He is currently serving as CEO of Curium Pharma’s SPECT and International businesses. Prior to that he served as Chief Commercial Officer of BTG plc, which he joined in 2011 and had roles leading both their Interventional Oncology and Interventional Vascular businesses as well as a period as Chief Development Officer accountable for Strategy, M&A and Market access. This culminated in an exit to Boston Scientific for $4.2 billion. Prior to BTG, John was Managing Director of Biocompatibles plc, building their Interventional Oncology business which led to a successful exit to BTG for £166.0 million. John joined Biocompatibles following a period as the Vice President of Marketing for Baxter Healthcare’s $750.0 million European Medication Delivery business based in Brussels then Zurich accountable for six strategic business units incorporating drugs, devices and drug device combinations. Before this, John held a number of senior commercial roles in the industrial sector. Immediately prior to Baxter Healthcare, John was the General Manager of a Minerals company with $4.0 billion of assets on three continents, $500.0 million of sales and 1500 employees. John graduated with joint honours in Biochemistry and Applied Molecular Biology from the University of Manchester Institute of Science and Technology U.M.I.S.T.. - John Sylvester于2019年7月被任命为公司董事。他目前担任Curium Pharma&8217；s SPECT和国际业务的首席执行官。此前，他曾担任BTG plc（他于2011年加入该公司）的首席商务官，并领导其介入肿瘤和介入血管业务，也曾担任首席开发官，负责战略、并购和市场准入。最终以42亿美元的价格退出波士顿科学公司。任职BTG公司之前，John曾担任BioComplobles plc的董事总经理，负责建立他们的介入肿瘤业务，从而以1.66亿英镑成功退出BTG公司。John加入BioConfectables公司之前，他曾担任Baxter梦百合公司的营销Vice President，负责位于布鲁塞尔的价值7.5亿新元的欧洲药物输送业务，随后加入苏黎世公司，负责六个战略业务部门，包括药物、设备和药物设备组合。在此之前，John在工业部门担任多个高级商业角色。在巴克斯特·梦百合之前，约翰是一家矿产公司的总经理，该公司在三大洲拥有40亿美元的资产，5亿美元的销售额和1500名员工。John以生物化学和应用分子生物学联合荣誉毕业于University of Manchester Institute of Science and Technology U.M.I.S.T.。
- John Sylvester was appointed as a director of the Company in July 2019. He is currently serving as CEO of Curium Pharma’s SPECT and International businesses. Prior to that he served as Chief Commercial Officer of BTG plc, which he joined in 2011 and had roles leading both their Interventional Oncology and Interventional Vascular businesses as well as a period as Chief Development Officer accountable for Strategy, M&A and Market access. This culminated in an exit to Boston Scientific for $4.2 billion. Prior to BTG, John was Managing Director of Biocompatibles plc, building their Interventional Oncology business which led to a successful exit to BTG for £166.0 million. John joined Biocompatibles following a period as the Vice President of Marketing for Baxter Healthcare’s $750.0 million European Medication Delivery business based in Brussels then Zurich accountable for six strategic business units incorporating drugs, devices and drug device combinations. Before this, John held a number of senior commercial roles in the industrial sector. Immediately prior to Baxter Healthcare, John was the General Manager of a Minerals company with $4.0 billion of assets on three continents, $500.0 million of sales and 1500 employees. John graduated with joint honours in Biochemistry and Applied Molecular Biology from the University of Manchester Institute of Science and Technology U.M.I.S.T..
- Gilad Aharon
-
Gilad Aharon于2020年5月被任命为公司董事。Aharon博士自2006年以来是Rosalind Advisors的联合创始人并担任投资组合经理。Aharon博士拥有多伦多大学（University of Toronto）的生物物理学和分子生物学博士学位。在联合创立Rosalind Advisors之前，Aharon博士在Infinium Securities Inc.担任股票分析师。
Gilad Aharon was appointed as a director of the Company in May 2020. Dr. Aharon is a co-founder of and has served as a Portfolio Manager at Rosalind Advisors, since 2006. Dr. Aharon holds a Ph.D. in Biophysics and Molecular Biology from the University of Toronto. Prior to cofounding Rosalind Advisors, Dr. Aharon worked as an equity analyst at Infinium Securities Inc. - Gilad Aharon于2020年5月被任命为公司董事。Aharon博士自2006年以来是Rosalind Advisors的联合创始人并担任投资组合经理。Aharon博士拥有多伦多大学（University of Toronto）的生物物理学和分子生物学博士学位。在联合创立Rosalind Advisors之前，Aharon博士在Infinium Securities Inc.担任股票分析师。
- Gilad Aharon was appointed as a director of the Company in May 2020. Dr. Aharon is a co-founder of and has served as a Portfolio Manager at Rosalind Advisors, since 2006. Dr. Aharon holds a Ph.D. in Biophysics and Molecular Biology from the University of Toronto. Prior to cofounding Rosalind Advisors, Dr. Aharon worked as an equity analyst at Infinium Securities Inc.
- Steven Salamon
-
Steven Salamon于2020年5月被任命为公司董事。Salamon自2006年起担任Rosalind Advisors，Inc.（一家专注于生命科学的投资经理“；Rosalind Advisors”；）联合创始人和投资组合经理。Salamon先生拥有艾维商学院（Ivey Business School）的工商管理硕士学位和多伦多大学（University of Toronto）的工程物理学位。在联合创立Rosalind Advisors之前，Salamon先生曾在汇丰证券（HSBC Securities）和加拿大皇家银行资本市场（RBC Dominion Securities）担任股票分析师。
Steven Salamon was appointed as a director of the Company in May 2020. Mr. Salamon is a co-founder of and has served as Portfolio Manager at Rosalind Advisors, Inc., a life sciences focused investment manager "Rosalind Advisors", since 2006. Mr. Salamon holds a MBA from the Ivey Business School and an Engineering Physics degree from the University of Toronto. Prior to co-founding Rosalind Advisors, Mr. Salamon worked as an equity analyst at HSBC Securities and RBC Capital Markets (formerly RBC Dominion Securities). - Steven Salamon于2020年5月被任命为公司董事。Salamon自2006年起担任Rosalind Advisors，Inc.（一家专注于生命科学的投资经理“；Rosalind Advisors”；）联合创始人和投资组合经理。Salamon先生拥有艾维商学院（Ivey Business School）的工商管理硕士学位和多伦多大学（University of Toronto）的工程物理学位。在联合创立Rosalind Advisors之前，Salamon先生曾在汇丰证券（HSBC Securities）和加拿大皇家银行资本市场（RBC Dominion Securities）担任股票分析师。
- Steven Salamon was appointed as a director of the Company in May 2020. Mr. Salamon is a co-founder of and has served as Portfolio Manager at Rosalind Advisors, Inc., a life sciences focused investment manager "Rosalind Advisors", since 2006. Mr. Salamon holds a MBA from the Ivey Business School and an Engineering Physics degree from the University of Toronto. Prior to co-founding Rosalind Advisors, Mr. Salamon worked as an equity analyst at HSBC Securities and RBC Capital Markets (formerly RBC Dominion Securities).
- Roger G. Stoll
-
Roger G. Stoll 博士 2008年12月他获委任为董事。2002年至2008年，他担任Cortex制药公司（OTCBB：CORX）的主席、行政总裁兼总裁。 2008年8月，他被任命为公司董事会执行主席。2012年8月他从皮质制药退休。2001年至2002年，他是几个东海岸风险投资公司和启动企业的顾问。1998年至2001年，他是北美费森尤斯医疗的执行副总裁，负责透析产品部门与诊断系统业务部门，其中包括血液透析机和透析过滤器设备。1991年至1998年，他是欧美达的首席执行官，一家麻醉剂和相关手术室设备和装置的全球领导者。他还担任了圣犹达医疗用品及中银集团有限公司的董事局。1986年至1991年，他在拜耳股份公司担任多个高级管理层职位，其中包括全球诊断业务集团的执行副总裁和总经理。在此之前，他曾任职于美国医院供应公司，在那里他从临床药理总监上升到美国重症护理部总裁。1972年他在普强公司开始了他的制药职业生涯。他获得了费里斯州立大学药剂学的学士学位，获得康涅狄格大学生物药剂学与药物代谢的博士学位，是密歇根大学就读两年的博士后。自2008年以来，他曾就职于切尔西治疗（NASDAQ：CHTP）董事会，并是董事会的审计委员会和薪酬委员会成员。他也就职于康涅狄格大学药学顾问委员会。
Roger G. Stoll was appointed as a director of the Company in December 2008. He became Executive Chairman in September 2014 and has served as Chairman of the Board since October 2015. From 2002 to 2008 he served as Chairman and Chief Executive Officer of Cortex Pharmaceuticals, Inc. now RespireRx Pharmaceuticals Inc.. In August of 2008 he was appointed Executive Chairman of the board of directors of Cortex and retired in 2012. From 2001 to 2002 he was a consultant to several east coast venture capital firms and startup ventures. From 1998 to 2001 he was Executive Vice President of Fresenius Medical Care-North America, in charge of the dialysis products division and the diagnostic business units, which included hemodialysis machines, dialysis filters, dialysate solutions, and attendant devices used in the dialysis procedure. From 1991 to 1998 Dr. Stoll was Chief Executive of Ohmeda, a global leader in anesthetic agents, critical care drugs and related operating room devices with sales of $1 billion annually. From 1994 until the sale of Ohmeda in 1998 he was also a member of the board of directors of The BOC Group, plc in London, UK (now part of Linde). From 1986 to 1991 Dr. Stoll held several positions of increasing responsibility at Bayer, AG including, Chief Administrative Officer, President of Consumer Healthcare business unit, and Executive Vice-President and General Manager for its worldwide Diagnostic Business Group which included the acquisition of The Tecnicon Company and globally integrating the Bayer and Techincon business units. This resulted in a global diagnostic business in excess of $1 billion in sales annually. Prior to that he worked for American Hospital Supply Corporation, where he rose from Director of Clinical Pharmacology to President of the American Critical Care drug division of AHSC. He began his pharmaceutical career at the Upjohn Company working in drug metabolism and pharmacokinetic studies in a clinical development unit in 1972. Dr. Stoll obtained his BS in Pharmacy degree at Ferris State University, his PhD in Biopharmaceutics and drug metabolism at the University of Connecticut and was a post-doctoral fellow for two years at the University of Michigan. He served on the boards of Agensys, Inc from 2003 until its sale to Astellas in late 2007 Questcor Pharmaceuticals from 1999 to 2004 and Chelsea Therapeutics until it was acquired in 2008 by Lundbeck A/S. From 1991 to 2002 Dr. Stoll also served on the board of directors of St. Jude Medical, HIMA and PMA (now PhRMA). Dr. Stoll also serves on the University of Connecticut School of Pharmacy Advisory Board. - Roger G. Stoll 博士 2008年12月他获委任为董事。2002年至2008年，他担任Cortex制药公司（OTCBB：CORX）的主席、行政总裁兼总裁。 2008年8月，他被任命为公司董事会执行主席。2012年8月他从皮质制药退休。2001年至2002年，他是几个东海岸风险投资公司和启动企业的顾问。1998年至2001年，他是北美费森尤斯医疗的执行副总裁，负责透析产品部门与诊断系统业务部门，其中包括血液透析机和透析过滤器设备。1991年至1998年，他是欧美达的首席执行官，一家麻醉剂和相关手术室设备和装置的全球领导者。他还担任了圣犹达医疗用品及中银集团有限公司的董事局。1986年至1991年，他在拜耳股份公司担任多个高级管理层职位，其中包括全球诊断业务集团的执行副总裁和总经理。在此之前，他曾任职于美国医院供应公司，在那里他从临床药理总监上升到美国重症护理部总裁。1972年他在普强公司开始了他的制药职业生涯。他获得了费里斯州立大学药剂学的学士学位，获得康涅狄格大学生物药剂学与药物代谢的博士学位，是密歇根大学就读两年的博士后。自2008年以来，他曾就职于切尔西治疗（NASDAQ：CHTP）董事会，并是董事会的审计委员会和薪酬委员会成员。他也就职于康涅狄格大学药学顾问委员会。
- Roger G. Stoll was appointed as a director of the Company in December 2008. He became Executive Chairman in September 2014 and has served as Chairman of the Board since October 2015. From 2002 to 2008 he served as Chairman and Chief Executive Officer of Cortex Pharmaceuticals, Inc. now RespireRx Pharmaceuticals Inc.. In August of 2008 he was appointed Executive Chairman of the board of directors of Cortex and retired in 2012. From 2001 to 2002 he was a consultant to several east coast venture capital firms and startup ventures. From 1998 to 2001 he was Executive Vice President of Fresenius Medical Care-North America, in charge of the dialysis products division and the diagnostic business units, which included hemodialysis machines, dialysis filters, dialysate solutions, and attendant devices used in the dialysis procedure. From 1991 to 1998 Dr. Stoll was Chief Executive of Ohmeda, a global leader in anesthetic agents, critical care drugs and related operating room devices with sales of $1 billion annually. From 1994 until the sale of Ohmeda in 1998 he was also a member of the board of directors of The BOC Group, plc in London, UK (now part of Linde). From 1986 to 1991 Dr. Stoll held several positions of increasing responsibility at Bayer, AG including, Chief Administrative Officer, President of Consumer Healthcare business unit, and Executive Vice-President and General Manager for its worldwide Diagnostic Business Group which included the acquisition of The Tecnicon Company and globally integrating the Bayer and Techincon business units. This resulted in a global diagnostic business in excess of $1 billion in sales annually. Prior to that he worked for American Hospital Supply Corporation, where he rose from Director of Clinical Pharmacology to President of the American Critical Care drug division of AHSC. He began his pharmaceutical career at the Upjohn Company working in drug metabolism and pharmacokinetic studies in a clinical development unit in 1972. Dr. Stoll obtained his BS in Pharmacy degree at Ferris State University, his PhD in Biopharmaceutics and drug metabolism at the University of Connecticut and was a post-doctoral fellow for two years at the University of Michigan. He served on the boards of Agensys, Inc from 2003 until its sale to Astellas in late 2007 Questcor Pharmaceuticals from 1999 to 2004 and Chelsea Therapeutics until it was acquired in 2008 by Lundbeck A/S. From 1991 to 2002 Dr. Stoll also served on the board of directors of St. Jude Medical, HIMA and PMA (now PhRMA). Dr. Stoll also serves on the University of Connecticut School of Pharmacy Advisory Board.
- Elizabeth Czerepak
-
Elizabeth Czerepak最近担任了以技术为核心的核酸递送公司Genevant Sciences的首席财务官和首席业务官。 在此之前，她曾在临床阶段生物制药公司Altimmune，Inc.担任首席财务官兼企业发展执行副总裁，并在那里领导了与PharmAthene，Inc.的反向合并。她在制药和生物技术行业的其他职位包括 Isarna Therapeutics的首席财务官兼首席运营官以及Cancer Genetics，Inc.的首席财务官。此外，Czerepak女士在贝尔斯登（Bear Stearns）和摩根大通（JPMorgan）担任前董事总经理以及BSHI的创始普通合伙人，拥有10年的风险投资经验。
Elizabeth Czerepak has served as Sorrento Therapeutics, Inc.'s Executive Vice President and Chief Financial Officer since May 2022. She has over 35 years of experience in big pharma, biotechnology and venture capital. Prior to joining Sorrento, Ms. Czerepak served as the Chief Financial Officer of BeyondSpring Inc. Nasdaq: BYSI, a global biopharmaceutical company focused on developing innovative immuno-oncology cancer therapies from September 2020 to May 2022. From May 2018 to January 2020 Ms. Czerepak served as the Chief Financial Officer and the Chief Business Officer of Genevant Sciences, Inc., a technology-focused lipid nanoparticle delivery company. From 2015 to 2018 she served as the Chief Financial Officer and Executive Vice President of Corporate Development of Altimmune, Inc., a clinical stage vaccines company, and from 2014 to 2015 she served as the Chief Financial Officer and the Chief Business Officer of Isarna Therapeutics Inc., which develops selective transforming growth factor beta inhibitors for cancer, ophthalmic and fibrotic diseases. From 2011 to 2014 Ms. Czerepak served as the Chief Financial Officer, Secretary, Principal Accounting Officer and Head of Human Resources at Cancer Genetics, Inc., a company that develops and commercializes molecular diagnostics. Prior to that, she served as a Managing Director at JPMorgan Chase & Co. and Bear, Stearns & Co., a General Partner at Bear Stearns Health Innoventures L.P., a venture capital fund and as a NASD (now FINRA) Registered Representative (Series 7 and Series 63). Since February 2020 Ms. Czerepak has served as a director and chair of the audit committee of Delcath Systems, Inc., an interventional oncology company focused on the treatment of liver cancer. Ms. Czerepak previously served on the board of directors of Spectrum Pharmaceuticals, Inc. from June 2019 to December 2020. Ms. Czerepak served on the board of directors of the Company from October 2021 until her appointment as the Company's Executive Vice President and Chief Financial Officer and previously served on the board of directors of Scilex Holding Company from September 2019 to October 2020. She holds a B.A. magna cum laude in Spanish and Mathematics Education from Marshall University and a M.B.A. from Rutgers University in 1982. In 2020 Ms. Czerepak earned a Corporate Director Certificate from Harvard Business School. - Elizabeth Czerepak最近担任了以技术为核心的核酸递送公司Genevant Sciences的首席财务官和首席业务官。 在此之前，她曾在临床阶段生物制药公司Altimmune，Inc.担任首席财务官兼企业发展执行副总裁，并在那里领导了与PharmAthene，Inc.的反向合并。她在制药和生物技术行业的其他职位包括 Isarna Therapeutics的首席财务官兼首席运营官以及Cancer Genetics，Inc.的首席财务官。此外，Czerepak女士在贝尔斯登（Bear Stearns）和摩根大通（JPMorgan）担任前董事总经理以及BSHI的创始普通合伙人，拥有10年的风险投资经验。
- Elizabeth Czerepak has served as Sorrento Therapeutics, Inc.'s Executive Vice President and Chief Financial Officer since May 2022. She has over 35 years of experience in big pharma, biotechnology and venture capital. Prior to joining Sorrento, Ms. Czerepak served as the Chief Financial Officer of BeyondSpring Inc. Nasdaq: BYSI, a global biopharmaceutical company focused on developing innovative immuno-oncology cancer therapies from September 2020 to May 2022. From May 2018 to January 2020 Ms. Czerepak served as the Chief Financial Officer and the Chief Business Officer of Genevant Sciences, Inc., a technology-focused lipid nanoparticle delivery company. From 2015 to 2018 she served as the Chief Financial Officer and Executive Vice President of Corporate Development of Altimmune, Inc., a clinical stage vaccines company, and from 2014 to 2015 she served as the Chief Financial Officer and the Chief Business Officer of Isarna Therapeutics Inc., which develops selective transforming growth factor beta inhibitors for cancer, ophthalmic and fibrotic diseases. From 2011 to 2014 Ms. Czerepak served as the Chief Financial Officer, Secretary, Principal Accounting Officer and Head of Human Resources at Cancer Genetics, Inc., a company that develops and commercializes molecular diagnostics. Prior to that, she served as a Managing Director at JPMorgan Chase & Co. and Bear, Stearns & Co., a General Partner at Bear Stearns Health Innoventures L.P., a venture capital fund and as a NASD (now FINRA) Registered Representative (Series 7 and Series 63). Since February 2020 Ms. Czerepak has served as a director and chair of the audit committee of Delcath Systems, Inc., an interventional oncology company focused on the treatment of liver cancer. Ms. Czerepak previously served on the board of directors of Spectrum Pharmaceuticals, Inc. from June 2019 to December 2020. Ms. Czerepak served on the board of directors of the Company from October 2021 until her appointment as the Company's Executive Vice President and Chief Financial Officer and previously served on the board of directors of Scilex Holding Company from September 2019 to October 2020. She holds a B.A. magna cum laude in Spanish and Mathematics Education from Marshall University and a M.B.A. from Rutgers University in 1982. In 2020 Ms. Czerepak earned a Corporate Director Certificate from Harvard Business School.
高管简历
中英对照 | 中文 | 英文- Gerard Michel
Gerard Michel，他于2014年6月加入Vericel公司，拥有制药行业跨多个功能领域的25年以上的经验。他拥有业务开发、筹集资金和执行成功的金融交易的丰富经验。他此前曾担任Biodel公司的首席财务官兼公司开发副总裁（从2007年11月到2014年5月），在那里他曾监管战略开发、融资和资本结构管理、营销努力、投资者关系，以及财务报告和内部控制。任职Biodel公司之前（从2002年8月到2007年11月），他曾担任NPS Pharmaceuticals公司的首席财务官兼公司开发副总裁，在那里他曾领导第一个银团皇室货币化。此前，他曾担任Booz Allen Hamilton公司的负责人，也曾担任Lederle Labs和Wyeth Labs的多种商业职务。他持有the University of Rochester School of Medicine的微生物学硕士学位、the Simon School of Business的工商管理硕士学位，以及the University of Rochester的生物学与地质学学士学位。
Gerard Michel was appointed to Delcath Systems, Inc. Board in October 2020. Mr. Michel has over 30 years of experience in the pharmaceutical and medical technology industries across multiple functional areas. Prior to joining the Company as its Chief Executive Officer on October 1 2020 he was Chief Financial Officer of Vericel Corp., a biopharmaceutical company, since June 2014 where he was a key member of the management team which integrated a transformative acquisition and revised the company's business model from a research focused company to a fully integrated, profitable commercial business. Mr. Michel also served as Chief Financial Officer and Vice President, Corporate Development of Biodel, Inc. from November 2007 to May 2014 and Chief Financial Officer and Vice President of Corporate Development of NPS Pharmaceuticals Inc. from August 2002 to November 2007. Prior to that, Mr. Michel was a Principal at Booz Allen and held a variety of commercial roles at both Lederle Labs and Wyeth Labs. Mr. Michel holds a M.S in Microbiology from the University of Rochester School of Medicine, an M.B.A. from the Simon School of Business, and a B.S. in both Biology and Geology from the University of Rochester.- Gerard Michel，他于2014年6月加入Vericel公司，拥有制药行业跨多个功能领域的25年以上的经验。他拥有业务开发、筹集资金和执行成功的金融交易的丰富经验。他此前曾担任Biodel公司的首席财务官兼公司开发副总裁（从2007年11月到2014年5月），在那里他曾监管战略开发、融资和资本结构管理、营销努力、投资者关系，以及财务报告和内部控制。任职Biodel公司之前（从2002年8月到2007年11月），他曾担任NPS Pharmaceuticals公司的首席财务官兼公司开发副总裁，在那里他曾领导第一个银团皇室货币化。此前，他曾担任Booz Allen Hamilton公司的负责人，也曾担任Lederle Labs和Wyeth Labs的多种商业职务。他持有the University of Rochester School of Medicine的微生物学硕士学位、the Simon School of Business的工商管理硕士学位，以及the University of Rochester的生物学与地质学学士学位。
- Gerard Michel was appointed to Delcath Systems, Inc. Board in October 2020. Mr. Michel has over 30 years of experience in the pharmaceutical and medical technology industries across multiple functional areas. Prior to joining the Company as its Chief Executive Officer on October 1 2020 he was Chief Financial Officer of Vericel Corp., a biopharmaceutical company, since June 2014 where he was a key member of the management team which integrated a transformative acquisition and revised the company's business model from a research focused company to a fully integrated, profitable commercial business. Mr. Michel also served as Chief Financial Officer and Vice President, Corporate Development of Biodel, Inc. from November 2007 to May 2014 and Chief Financial Officer and Vice President of Corporate Development of NPS Pharmaceuticals Inc. from August 2002 to November 2007. Prior to that, Mr. Michel was a Principal at Booz Allen and held a variety of commercial roles at both Lederle Labs and Wyeth Labs. Mr. Michel holds a M.S in Microbiology from the University of Rochester School of Medicine, an M.B.A. from the Simon School of Business, and a B.S. in both Biology and Geology from the University of Rochester.
- Johnny John
Johnny John Delcath Systems, Inc.临床开发和医疗事务高级副总裁，于2012年3月19日加入公司，担任临床运营总监，2021年2月晋升为现职。John博士在肿瘤药物开发和临床试验领域工作了超过17年。在加入Delcath之前，他于2004年至2012年在InVentiv Health（现已更名为Syneos Health, Inc.）从事临床试验运营工作，为各种肿瘤学项目提供临床和医学监督，包括导致Ipilimumab获得FDA批准的试验。在InVentiv Health之前，John博士在临床实践中花费了超过11年的时间。他在印度芒格洛尔大学获得医学学位，并在伊利诺伊大学接受研究生培训。
Johnny John Delcath Systems, Inc. Senior Vice President Clinical Development and Medical Affairs, joined the Company on March 19, 2012 as Director, Clinical Operations and was promoted to his current position in February 2021. Dr. John has worked in oncology drug development and clinical trials for over 17 years. Prior to joining Delcath, he worked in Clinical Trial Operations at InVentiv Health (now renamed Syneos Health, Inc.) from 2004 to 2012 providing clinical and medical oversight on various oncology programs, including the trials that resulted in the FDA approval of Ipilimumab. Prior to InVentiv Health, Dr. John spent over 11 years in clinical practice. He received his medical degree from Mangalore University, India and postgraduate training at the University of Illinois.- Johnny John Delcath Systems, Inc.临床开发和医疗事务高级副总裁，于2012年3月19日加入公司，担任临床运营总监，2021年2月晋升为现职。John博士在肿瘤药物开发和临床试验领域工作了超过17年。在加入Delcath之前，他于2004年至2012年在InVentiv Health（现已更名为Syneos Health, Inc.）从事临床试验运营工作，为各种肿瘤学项目提供临床和医学监督，包括导致Ipilimumab获得FDA批准的试验。在InVentiv Health之前，John博士在临床实践中花费了超过11年的时间。他在印度芒格洛尔大学获得医学学位，并在伊利诺伊大学接受研究生培训。
- Johnny John Delcath Systems, Inc. Senior Vice President Clinical Development and Medical Affairs, joined the Company on March 19, 2012 as Director, Clinical Operations and was promoted to his current position in February 2021. Dr. John has worked in oncology drug development and clinical trials for over 17 years. Prior to joining Delcath, he worked in Clinical Trial Operations at InVentiv Health (now renamed Syneos Health, Inc.) from 2004 to 2012 providing clinical and medical oversight on various oncology programs, including the trials that resulted in the FDA approval of Ipilimumab. Prior to InVentiv Health, Dr. John spent over 11 years in clinical practice. He received his medical degree from Mangalore University, India and postgraduate training at the University of Illinois.
- John Purpura
John Purpura 2009年11月他加入Delcath，担任法规事务和质量保证的执行副总裁。加盟Delcath之前，他在EZ-EM公司担任副总裁，然后2007至2008年担任国际法规事务的执行总监；2008至2009年，担任北美和拉丁美洲法规事务的主管。在EZ-EM公司之前，他在Sanofi-Aventis公司有11年的职业生涯，2005至2007年最终担任CMC监管的助理副总裁。1985年至1995年，他在Bolar 制药、Luitpold制药和 Eon Labs 制造担任各种各样的质量和法规管理职务。他获得了纽约州立大学石溪分校管理与政策的理科硕士学位；化学和生物学的理学士学位。
John Purpura joined the Company as Executive Vice President, Regulatory Affairs and Quality Assurance in November 2009 and was promoted to Executive Vice President, Global Head of Operations on July 19 2016. He also served as Interim Chief Executive Officer of the Company from June 1 2020 to October 1 2020. Prior to joining the Company, he was with Bracco Diagnostics formerly E-Z-EM,Inc. as Vice President and then Executive Director of International Regulatory Affairs from 2007 to 2008 and Head of Regulatory Affairs for North America and Latin America from 2008 to 2009. Prior to E-Z-EM, Inc., Mr. Purpura had an 11-year career with Sanofi-Aventis, ultimately serving as Associate Vice President for Regulatory CMC from 2005 to 2007. From 1985 to 1995 he had various quality and regulatory management roles with Bolar Pharmaceuticals, Luitpold Pharmaceuticals and Eon Labs Manufacturing. He earned his M.S. in Management & Policy and B.S. degrees in Chemistry and Biology at the State University of New York at Stony Brook.- John Purpura 2009年11月他加入Delcath，担任法规事务和质量保证的执行副总裁。加盟Delcath之前，他在EZ-EM公司担任副总裁，然后2007至2008年担任国际法规事务的执行总监；2008至2009年，担任北美和拉丁美洲法规事务的主管。在EZ-EM公司之前，他在Sanofi-Aventis公司有11年的职业生涯，2005至2007年最终担任CMC监管的助理副总裁。1985年至1995年，他在Bolar 制药、Luitpold制药和 Eon Labs 制造担任各种各样的质量和法规管理职务。他获得了纽约州立大学石溪分校管理与政策的理科硕士学位；化学和生物学的理学士学位。
- John Purpura joined the Company as Executive Vice President, Regulatory Affairs and Quality Assurance in November 2009 and was promoted to Executive Vice President, Global Head of Operations on July 19 2016. He also served as Interim Chief Executive Officer of the Company from June 1 2020 to October 1 2020. Prior to joining the Company, he was with Bracco Diagnostics formerly E-Z-EM,Inc. as Vice President and then Executive Director of International Regulatory Affairs from 2007 to 2008 and Head of Regulatory Affairs for North America and Latin America from 2008 to 2009. Prior to E-Z-EM, Inc., Mr. Purpura had an 11-year career with Sanofi-Aventis, ultimately serving as Associate Vice President for Regulatory CMC from 2005 to 2007. From 1985 to 1995 he had various quality and regulatory management roles with Bolar Pharmaceuticals, Luitpold Pharmaceuticals and Eon Labs Manufacturing. He earned his M.S. in Management & Policy and B.S. degrees in Chemistry and Biology at the State University of New York at Stony Brook.